when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Bispecific Antibody · news · pharmadog

← back to Bispecific Antibody

News · Bispecific Antibody

209 stories

Jul 27, 26Legend Biotech CEO abruptly steps down without permanent replacementfiercebiotech

Jul 27, 26Summit, Merck must navigate new regulatory terrain in China-first cancer landscapebiospace

Jul 24, 26Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomabiopharma dive

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

Jul 24, 26Roche cans one Carmot obesity asset as another shows best-in-class potentialbiospace

Jul 23, 26Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesfiercebiotech

Jul 22, 26Summit and Akeso sharpen case for ivonescimab with new Western databiospace

Jul 17, 26Jasper gets a lifeline in merger with immune drugmaker Kirabiopharma dive

Jul 6, 26Cancer, immune drugmakers dominate VC funding so far in 2026biopharma dive

Jul 1, 26STAT+: Booze schmooze: The alcohol industry, frazzled by headwinds, wields its power behind the scenesstat

Jun 30, 26AbbVie and Genmab's latest win brings Epkinly closer to label expansionendpoints

Jun 30, 26These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.biopharma dive

Jun 30, 26STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordiskstat

Jun 30, 26STAT+: Abivax seeks to ease safety concerns with new data, boosting sharesstat

Jun 29, 265 takeaways from STAT’s investigation into microhospital operator Nutex Healthstat

Jun 26, 26On second try, Acadia drug gets nod from European regulatorsbiopharma dive

Jun 17, 26Jazz zeroes in on next-gen T cell engagers with AbCellera dealbiopharma dive

Jun 15, 26J&J multiple myeloma drug gains edge in earlier stage diseasebiopharma dive

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

Jun 3, 26NewLimit’s $435M megaround; Lilly’s busy dealmaking weekbiopharma dive

Jun 2, 26ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancerbiopharma dive

Jun 1, 26RallyBio tries again for reverse merger, this time with Avenzobiopharma dive

Jun 1, 26STAT+: A turning point for pancreatic cancer patientsstat

May 31, 26STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancerstat

May 30, 26STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDAstat

May 29, 26Bristol Myers unveils data for one of its next-gen blood cancer drugsbiopharma dive

May 19, 26A migraine drugmaker heads to the public markets through reverse mergerbiopharma dive

May 13, 26Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practiceonclive

May 13, 26FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLonclive

May 13, 26FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphomaonclive

← prevpage 4 of 7next →